IVAC's Covid-19 vaccine has been tested on animals, such as yellow  mice, rats, rabbits nad etc. The results showed that the vaccine creates high immunity in animals. Vaccine has been evaluated for safety, immunity, protective effect in animals. Therefore, IVAC submits to the Ministry of Health for human trials, scheduled for the end of January 2021.

Before that, IVAC planned a clinical trial in March 2021. Thus, the research progress is faster nearly 2 months.

IVAC began conducting Covivac vaccine research in May 2020 with the goal of producing the vaccine and completing a three-phase clinical trial in 18 months.

According to the plan, IVAC coordinates with the National Institute of Hygiene and Epidemiology (NIHE), Hanoi Medical University for clinical trials of vaccines. The vaccine will be divided into different doses for different injections and tested in many groups of subjects, through 3 phases. Estimated dose for each subject is 1 mcg, 3 mcg and each subject injected 2 doses 28 days.

During that process, IVAC and other units of the Ministry of Health will monitor the situation of volunteers, and proceed smoothly, the next steps will be taken.

Volunteers participate in the 1-year-old trial from 18 to 59, healthy, have no underlying disease and are well screened, among other specific criteria. Phase 1 ended in April 2020.

If the results of the three phases are good, the second Covid-19 vaccine from Vietnam will appear the market by the end of 2021.

It is known that IVAC uses culture technology on chicken eggs with embryos to carry out the production process of Covid-19 vaccine similar to the already established A / H5N1 vaccine with a capacity of 3 million doses per year.

When research on Covid-19 vaccine production, the institute used strain NDV-LaSota-S as a vector of S protein expression of SARS-CoV-2. This is a low virulence strain that is used in many vaccines.